Top Stem Cells Stocks

There hasn't been much debate in the press recently about stem cells, however, there has been plenty of news.  For example, a mini-kidney was grown from stem cells by scientists. Researchers have now found a way to grow aged brain cells from stem cells. And finally, Plantar Fasciitis is now being treated with stem cells.

Extensive stem cell research is being done relating to the treatment of cancer, Parkinson's disease, and multiple sclerosis. Due to all the controversy about embryonic stem cells,  alternative sources are being studied, such a teeth and umbilical cord blood.

Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $24.6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 71 and a forward PE of 37. Earnings for the latest quarter were up 1.7%% on a 36.1% boost in revenues.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The company recently generated a 59 cent loss per share on a 1.5% increase in sales. It has a market cap of $1.34 billion.

Cellgene (CELG) is a $69.6 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. They have a patent on placental stem cell recovery. The stock sports a PE ratio of 49 and a forward PE of 23. Quarterly earnings were down 12.2%% on an 18%% revenue increase.

For a free list of twenty stocks involved in stem cell research, along with some cord blood stocks, which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cells Developed from Blood: Top Stem Cell Companies

Stem cells therapies are currently used in bone marrow transplants that are used to treat leukemia, and scientists believe in the future, they can be used to treat cancer, Parkinson's disease, and multiple sclerosis. Researchers at the at the University of Cambridge have developed a way of producing stem cells with blood. The research was published in the Stem Cells: Translational Medicine journal. With all the controversy about embryonic stem cells, scientists are looking for alternative sources, such a teeth and umbilical cord blood.

Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $18.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 85 and a forward PE of 42.6. Earnings for the latest quarter were up an incredible 40.6%% on a 44.2% boost in revenues.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 33 times current earnings, and 12 times forward earnings. However, earnings for the latest quarter were up a strong 17.5% on a 3.9% rise in sales.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 22 and a forward PE of 14. Quarterly earnings were up 13.7%% on a 13.6%% revenue increase.

For a free list of twenty stocks involved in stem cell research, along with some cord blood stocks, which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Stocks

On Sunday evening, 60 Minutes broadcast an extensive report on stem cell scams. It reported on companies around the world that make outrageous claims with regards to the treatment and cures that stem cells can provide. Numerous people who have incurable diseases are desperately looking for cures, and are being taking advantage of by charlatans purporting to solve all their medical issues.

However, stem cells are being used currently for medical treatments. Look at bone marrow transplants that are used to treat leukemia utilizing adult stem cells. Scientists are actively looking at stem cells to treat diseases such as cancer, Parkinson's disease, and spinal cord injuries.

There are actually many publicly traded companies involved in stem cell research. WallStreetNewsNetwork.com has turned up over 20 stem cell stocks, half of which are currently profitable.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 17 times current earnings, and 7.5 times forward earnings. However, earnings for the latest quarter were down 31.8%.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $13.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 92 and a forward PE of 45. Earnings for the latest quarter were up an amazing 135.2% on a 44% rise in revenues.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 15. Quarterly earnings were up 32.7% on a 37% revenue increase.

For a free list of over twenty stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Funding Ban Reversed: What About the Stocks?

Last week was a busy week for stem cells. The suspension of Federal funding for stem cell research has just been overturned by a United States Appeals Court. The two to one ruling last week said that the law against Federal funding was ambiguous. In addition, Dr. Paul Sharpe spoke at the First International Conference on Dental and Craniofacial Stem Cells in New York last week. He discussed the use of regenerative dentistry to regrow teeth with dental stem cells.

Research has been continuing into the use of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. There are several publicly traded companies in the stem cell field, according to the free list of stem cell stocks at WallStreetNewsNetwork.com.

For example, Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 93 and a forward PE of 32.

Cellgene (CELG) is a $27.4 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 31 and a forward PE of 14.

Integra Lifesciences Holdings (IART) is a New Jersey based $1.5 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 24 times current earnings, and 16 times forward earnings.

For a free list of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Stocks Are Growing

According to the latest Journal of the Congress of Neurological Surgeons Research, Neurosurgery, bone marrow stem cells derived from a patient's own bone marrow were safely used in pediatric patients with severe traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

Research has been continuing into the utilization of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just updated its free downloadable list of over ten stem cell stocks. Can one of these provide a cure for your portfolio?

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a PE of 94 and a forward PE of 33.

Cellgene (CELG) is a $24.7 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 13.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 22 times earnings, and 14.5 times forward earnings.

For a database of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

First US Trial of Embryonic Stem Cells in Humans

The Food and Drug Administration has given the go ahead to Geron (GERN) to use human embryonic stem cells in human patients. The trial study will be sued to treat patients with spinal injuries. Previous studies have shown that paralyzed rats have achieved some movement after treatment.

Geron, which has expended $170 million on stem cell research, was up about 6% today on the news. The stock generated a quarterly loss of 73 cents for the latest reported quarter, however, revenues were up 447% during the same time frame. The company will report earnings on October 28. This debt free company has $1.19 in cash per share.

Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, macular degeneration, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com developed a downloadable list of over ten stem cell stocks. Hopefully your portfolio will receive a cure with one of these companies. Here is a list of a few opportunities.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 20 and a forward PE of 28.

Cellgene (CELG) is a $26 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. The company also received patent on placental stem cell recovery. The stock sports a PE of 31 and a forward PE of 17.

Integra LifeSciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The P/E is 19, and the forward PE is 13.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Disclosure: Author does not own any of the above at the time the article was written.

By Stockerblog.com

Top Stem Cell Stocks

In March of last year, President Barack Obama signed an executive order to eliminate a ban on federal funding for embryonic stem-cell research. This policy change should cause a substantial increase in research into stem cell therapy. Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions.

Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just came up with a downloadable list of over ten stem cell stocks. Maybe one of these will provide a cure for your portfolio.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $4.7 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 15.9 and a forward PE of 21.6.

Cellgene (CELG) is a $24.3 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received patent on placental stem cell recovery. The stock sports a PE of 29 and a forward PE of 16.5.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. Their P/E is 17.8, and the forward PE is 11.5.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Author does not own any of the above.

By Stockerblog.com